Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 431

1.

Second-generation thiazolidinediones and hepatotoxicity.

Marcy TR, Britton ML, Blevins SM.

Ann Pharmacother. 2004 Sep;38(9):1419-23. Epub 2004 Jul 20.

PMID:
15266041
2.

Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma.

El-Naggar MH, Helmy A, Moawad M, Al-Omary M, Al-Kadhi Y, Habib B.

Ann Pharmacother. 2008 May;42(5):713-8. doi: 10.1345/aph.1K543. Epub 2008 Apr 8.

PMID:
18397974
3.
4.

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.

May LD, Lefkowitch JH, Kram MT, Rubin DE.

Ann Intern Med. 2002 Mar 19;136(6):449-52.

PMID:
11900497
5.

Case series of liver failure associated with rosiglitazone and pioglitazone.

Floyd JS, Barbehenn E, Lurie P, Wolfe SM.

Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1238-43. doi: 10.1002/pds.1804.

PMID:
19623674
6.

Thiazolidinedione-induced congestive heart failure.

Cheng AY, Fantus IG.

Ann Pharmacother. 2004 May;38(5):817-20. Epub 2004 Mar 23.

PMID:
15039476
7.

Hepatotoxicity with thiazolidinediones: is it a class effect?

Scheen AJ.

Drug Saf. 2001;24(12):873-88. Review.

PMID:
11735645
8.

Hepatotoxicity of thiazolidinediones.

Isley WL.

Expert Opin Drug Saf. 2003 Nov;2(6):581-6. Review.

PMID:
14585066
9.

Methylprednisolone-induced toxic hepatitis.

Topal F, Ozaslan E, Akbulut S, Küçükazman M, Yüksel O, Altiparmak E.

Ann Pharmacother. 2006 Oct;40(10):1868-71. Epub 2006 Aug 22.

PMID:
16926305
10.

Thiazolidinedione hepatotoxicity: a class effect?

Tolman KG.

Int J Clin Pract Suppl. 2000 Oct;(113):29-34. Review.

PMID:
11965828
11.

Thiazolidinediones and liver toxicity.

Scheen AJ.

Diabetes Metab. 2001 Jun;27(3):305-13. Review.

12.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
13.

Possible metformin-induced hepatotoxicity.

Kutoh E.

Am J Geriatr Pharmacother. 2005 Dec;3(4):270-3.

PMID:
16503324
14.
15.

Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

Tolman KG, Freston JW, Kupfer S, Perez A.

Drug Saf. 2009;32(9):787-800. doi: 10.2165/11316510-000000000-00000.

PMID:
19670918
16.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
17.

How safe is the use of thiazolidinediones in clinical practice?

Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821 . Review.

PMID:
19236215
18.

Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.

Hurren KM, Taylor TN, Jaber LA.

Diabetes Res Clin Pract. 2011 Jul;93(1):49-55. doi: 10.1016/j.diabres.2011.02.035. Epub 2011 Mar 25.

PMID:
21440324
19.

Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors.

Gegick CG, Altheimer MD.

Curr Med Res Opin. 2004 Jun;20(6):919-30.

PMID:
15200751
20.

Hepatotoxicity associated with acarbose therapy.

Hsiao SH, Liao LH, Cheng PN, Wu TJ.

Ann Pharmacother. 2006 Jan;40(1):151-4. Epub 2005 Nov 29.

PMID:
16317107
Items per page

Supplemental Content

Write to the Help Desk